Brean Capital Reiterates $8.00 Price Target for Intellipharmaceutics International Inc. (IPCI)
IPCI has been the subject of several other reports. Maxim Group set a $6.00 price target on Intellipharmaceutics International and gave the stock a buy rating in a research report on Thursday, October 6th. Zacks Investment Research cut Intellipharmaceutics International from a buy rating to a hold rating in a research report on Wednesday, September 14th.
Intellipharmaceutics International (NASDAQ:IPCI) opened at 2.90 on Monday. The stock’s market cap is $83.37 million. Intellipharmaceutics International has a 52 week low of $1.41 and a 52 week high of $3.33. The stock’s 50 day moving average price is $2.06 and its 200 day moving average price is $1.86.
Intellipharmaceutics International (NASDAQ:IPCI) last issued its quarterly earnings results on Wednesday, July 13th. The company reported ($0.08) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. Intellipharmaceutics International had a negative return on equity of 832.00% and a negative net margin of 325.20%. On average, analysts forecast that Intellipharmaceutics International will post ($0.28) earnings per share for the current year.
A hedge fund recently raised its stake in Intellipharmaceutics International stock. Atria Investments LLC boosted its stake in Intellipharmaceutics International Inc. (NASDAQ:IPCI) by 12.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 75,895 shares of the company’s stock after buying an additional 8,168 shares during the period. Atria Investments LLC owned approximately 0.26% of Intellipharmaceutics International worth $159,000 as of its most recent filing with the SEC. 1.30% of the stock is owned by institutional investors.
About Intellipharmaceutics International
Intellipharmaceutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.